Cartier Cuts 12.4 g/t Au over 5.0 m Doubling Resource Potential of Zones 5NE and 5M4

Highlights:
Goldplay Exploration Ltd. (TSXV: GPLY, FRANKFURT: GPE OTCQB: GLYXF) (“Goldplay” or the “Company”) is pleased to announce the listing of its shares on the Frankfurt Stock Exchange under the symbol GPE effective January 15, 2019.
MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to report that shareholders voted in favor of all resolutions brought forth at the Company’s annual general and special meeting of shareholders (the “Meeting”) held on Friday, January 11, 2019 in Vancouver, British Columbia.
Millennial Lithium Corp. (TSXV: ML) (FSE: A3N2) (OTCQX: MLNLF) (“Millennial” or the “Company”) is pleased to report that bench scale process test work completed by SGS Canada Inc. (SGS) in their facilities in Lakefield, ON on brine from the Company’s Pastos Grandes project in Salta, Argentina, has yielded battery grade (> 99.5% Li2CO3) lithium carbonate. Final purification testwork results yielded a lithium carbonate product that is 99.92% Li2CO3 with low levels of magnesium (Mg), calcium (Ca), boron (B), sulphate (SO4) and iron (Fe), with no other detectable metals.
Marathon Gold Corporation (“Marathon” or the “Company”) (TSX: MOZ), a growth focused gold exploration and development company, provides a summary of our accomplishments in 2018 and plans for 2019.
White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company“) and Comstock Metals Ltd. (TSX.V: CSL) (“Comstock” or the “Vendor”) are pleased to announce that they have entered into a binding letter agreement dated January 11, 2019 pursuant to which the Company will purchase from the Vendor the property known as the QV Gold Project (the “Property”) subject to the terms and conditions therein (the “Acquisition”). The Property covers 16,335 hectares (40,000 acres) in the Yukon’s White Gold District, bringing the Company’s total holdings in the White Gold District to 439,000 hectares (1,080,000 acres). The QV Gold Project is contiguous to the Company’s White Gold property which hosts its Golden Saddle and Arc deposits, 20 km southwest of the Company’s Vertigo Discovery on its JP Ross property and 44 kilometres northwest of Goldcorp Inc.’s (TSX: G, NYSE: GG) Coffee project. The Company looks forward to incorporating the Property into its systematic and data driven regional exploration program backed by partners Agnico Eagle Mines Limited (TSX: AEM, NYSE: AEM) and Kinross Gold Corp (TSX: K, NYSE: KGC).
FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange (“CSE”) today under the stock symbol “LOVE”. FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares”) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.
Aben Resources Ltd. (TSX-V: ABN) (OTCQB: ABNAF) (Frankfurt: E2L2) (the “Company”) is pleased to provide a summary of exploration results from the 2018 exploration program on their 100% owned Justin Gold Project in the Yukon Territory. Work completed in 2018 included the collection of 19 channel and 28 chip samples from 5 trenches, 16 rock samples, 7 till samples and 240 soil samples with coverage totaling 6.0 line-km. The 2018 field program focused primarily on the Lost Ace Zone, a gold bearing zone discovered in 2017. Lost Ace is located 2 kilometers west of Aben’s POW Zone where past drill results indicate potential for bulk-tonnage gold mineralization with intercepts reported ranging from trace values to highs of 1.19 g/t Au over 60.0 m (including 2.47 g/t Au over 21.0 m) and 1.49 g/t Au over 46.4 m.
FSD Pharma (“FSD“) announced today that, in connection with the business combination (the “Business Combination“) completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the “Issuer“), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares (“Common Shares“) of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.
30 day pumping test continuing in CAU07, averaging 647 mg/l lithium
CAU11 pumping test completed averaging 512 mg/l lithium